LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: Successful use of thrombopoietin analogs in thrombocytopenia associated with MYH-9 mutation.

    Louzao, María / Vargas, María Teresa / Meseguer, Emma / Pedrote Amador, Begoña / Perez Simón, Jose Antonio / Mingot-Castellano, María Eva

    Annals of hematology

    2023  Volume 102, Issue 11, Page(s) 3283–3284

    MeSH term(s) Humans ; Thrombopoietin/genetics ; Thrombopoietin/therapeutic use ; Thrombocytopenia/drug therapy ; Thrombocytopenia/genetics ; Mutation ; Anemia
    Chemical Substances Thrombopoietin (9014-42-0)
    Language English
    Publishing date 2023-08-23
    Publishing country Germany
    Document type Letter
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-023-05386-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.

    Santoro, Cristina / Fuh, Beng / Le, Phu Quoc / Maes, Philip / Berrueco, Rubén / Mingot-Castellano, Eva Maria / von Mackensen, Sylvia / Tueckmantel, Claudia / Cabre-Marquez, Jose Francisco / Wang, Michael

    European journal of haematology

    2022  Volume 110, Issue 1, Page(s) 77–87

    Abstract: Objectives: To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry®/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A.: Methods: ... ...

    Abstract Objectives: To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry®/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A.
    Methods: TAURUS (NCT02830477) is a phase 4, multinational, prospective, non-interventional, single-arm study in patients of any age with moderate or severe haemophilia A (≤5% factor [F]VIII activity). TAURUS was designed to primarily investigate weekly prophylaxis dosing regimens used in standard clinical practice. Annualised bleeding rates (ABRs), treatment satisfaction and adherence, and safety were also assessed.
    Results: Of 302 patients included in the full analysis set, 84.4% (n = 255) maintained their octocog alfa prophylaxis baseline regimen throughout the study, with a majority of patients (76.5%, n = 231) on two times or three times weekly regimens at the end of the observation period (≥1-≤2 years). ABRs, treatment satisfaction, and adherence remained stable during the observation period. Octocog alfa was well tolerated and there were no new or unexpected adverse events.
    Conclusions: These data show that a smooth transition is observed when switching to octocog alfa from a previous FVIII treatment, with no safety issues and stable bleeding rates in a real-world setting of patients with moderate-to-severe haemophilia A.
    MeSH term(s) Humans ; Factor VIII/adverse effects ; Hemophilia A/drug therapy ; Hemorrhage/prevention & control ; Hemorrhage/chemically induced ; Prospective Studies ; Treatment Outcome
    Chemical Substances F8 protein, human (839MOZ74GK) ; Factor VIII (9001-27-8)
    Language English
    Publishing date 2022-10-17
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13876
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973)

    Santoro, Cristina / Fuh, Beng / Phu Quoc Le / Maes, Philip / Berrueco, Rubén / Mingot-Castellano, Eva Maria / von Mackensen, Sylvia / Tueckmantel, Claudia / Francisco Cabre-Marquez, Jose / Wang, Michael

    European Journal of Haematology

    Final results of the global real-world study, TAURUS

    2023  Volume 110, Issue 1, Page(s) 77–87

    Abstract: Objectives: To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry (R)/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A. Methods: ... ...

    Title translation Wirksamkeit und Sicherheit bei Patienten mit Hämophilie A, die auf Octocog alfa (BAY 81-8973) umgestellt werden: Endgültige Ergebnisse der globalen Studie TAURUS unter Realbedingungen (DeepL)
    Abstract Objectives: To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry (R)/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe haemophilia A. Methods: TAURUS (NCT02830477) is a phase 4, multinational, prospective, non-interventional, single-arm study in patients of any age with moderate or severe haemophilia A (<= 5% factor [F]VIII activity). TAURUS was designed to primarily investigate weekly prophylaxis dosing regimens used in standard clinical practice. Annualised bleeding rates (ABRs), treatment satisfaction and adherence, and safety were also assessed. Results: Of 302 patients included in the full analysis set, 84.4% (n = 255) maintained their octocog alfa prophylaxis baseline regimen throughout the study, with a majority of patients (76.5%, n = 231) on two times or three times weekly regimens at the end of the observation period (>= 1-<= 2 years). ABRs, treatment satisfaction, and adherence remained stable during the observation period. Octocog alfa was well tolerated and there were no new or unexpected adverse events. Conclusions: These data show that a smooth transition is observed when switching to octocog alfa from a previous FVIII treatment, with no safety issues and stable bleeding rates in a real-world setting of patients with moderate-to-severe haemophilia A.
    Keywords Client Satisfaction ; Compliance (Behandlung) ; Hemophilia ; Hämophilie ; Prophylactic Drug Therapy ; Prophylaktische medikamentöse Therapie ; Safety ; Sicherheit (Unfallverhütung) ; Therapieergebnisse ; Treatment Compliance ; Treatment Outcomes ; Zufriedenheit von Klientinnen und Klienten
    Language English
    Document type Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13876
    Database PSYNDEX

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.

    Jiménez-Bárcenas, Reyes / García-Donas-Gabaldón, Gloria / Campos-Álvarez, Rosa María / Fernández-Sánchez de Mora, María Carmen / Luis-Navarro, Josefa / Domínguez-Rodríguez, Juan Francisco / Nieto-Hernández, María Del Mar / Sánchez-Bazán, Irene / Yera-Cobo, Maria / Cardesa-Cabrera, Rocio / Jiménez-Gonzalo, Francisco José / Ruiz-Cobo, María Antonia / Caparrós-Miranda, Isabel / Entrena-Ureña, Laura / Fernández Jiménez, Dolores / Díaz-Canales, Dana / Moreno-Carrasco, Gloria / Calderón-Cabrera, Cristina / Núñez-Vázquez, Ramiro José /
    Pedrote-Amador, Begoña / Mingot-Castellano, María Eva

    British journal of haematology

    2024  

    Abstract: Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are ... ...

    Abstract Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 10
    Language English
    Publishing date 2024-04-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: COVID-19 Vaccines and Autoimmune Hematologic Disorders.

    Mingot-Castellano, María Eva / Butta, Nora / Canaro, Mariana / Gómez Del Castillo Solano, María Del Carmen / Sánchez-González, Blanca / Jiménez-Bárcenas, Reyes / Pascual-Izquierdo, Cristina / Caballero-Navarro, Gonzalo / Entrena Ureña, Laura / José González-López, Tomás / On Behalf Of The Gepti

    Vaccines

    2022  Volume 10, Issue 6

    Abstract: Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally ... ...

    Abstract Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.
    Language English
    Publishing date 2022-06-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines10060961
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Novel Therapies to Address Unmet Needs in ITP.

    Mingot-Castellano, María Eva / Bastida, José María / Caballero-Navarro, Gonzalo / Entrena Ureña, Laura / González-López, Tomás José / González-Porras, José Ramón / Butta, Nora / Canaro, Mariana / Jiménez-Bárcenas, Reyes / Gómez Del Castillo Solano, María Del Carmen / Sánchez-González, Blanca / Pascual-Izquierdo, Cristina / On Behalf Of The Gepti

    Pharmaceuticals (Basel, Switzerland)

    2022  Volume 15, Issue 7

    Abstract: Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP ... ...

    Abstract Primary immune thrombocytopenia (ITP) is an autoimmune disorder that causes low platelet counts and subsequent bleeding risk. Although current corticosteroid-based ITP therapies are able to improve platelet counts, up to 70% of subjects with an ITP diagnosis do not achieve a sustained clinical response in the absence of treatment, thus requiring a second-line therapy option as well as additional care to prevent bleeding. Less than 40% of patients treated with thrombopoietin analogs, 60% of those treated with splenectomy, and 20% or fewer of those treated with rituximab or fostamatinib reach sustained remission in the absence of treatment. Therefore, optimizing therapeutic options for ITP management is mandatory. The pathophysiology of ITP is complex and involves several mechanisms that are apparently unrelated. These include the clearance of autoantibody-coated platelets by splenic macrophages or by the complement system, hepatic desialylated platelet destruction, and the inhibition of platelet production from megakaryocytes. The number of pathways involved may challenge treatment, but, at the same time, offer the possibility of unveiling a variety of new targets as the knowledge of the involved mechanisms progresses. The aim of this work, after revising the limitations of the current treatments, is to perform a thorough review of the mechanisms of action, pharmacokinetics/pharmacodynamics, efficacy, safety, and development stage of the novel ITP therapies under investigation. Hopefully, several of the options included herein may allow us to personalize ITP management according to the needs of each patient in the near future.
    Language English
    Publishing date 2022-06-23
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph15070779
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.

    Mingot-Castellano, María-Eva / García-Candel, Faustino / Martínez-Nieto, Jorge / García-Arroba, José / de la Rubia-Comos, Javier / Gómez-Seguí, Inés / Paciello-Coronel, María-Liz / Valcárcel-Ferreiras, David / Jiménez, Moraima / Cid, Joan / Lozano, Miquel / García-Gala, José-María / Angós-Vazquez, Sonia / Vara-Pampliega, Miriam / Guerra-Domínguez, Luisa / Ávila-Idrobo, Laura-Francisca / Oliva-Hernandez, Ana / Zalba-Marcos, Saioa / Tallón-Ruiz, Inmaculada /
    Ortega-Sánchez, Sandra / Goterris-Viciedo, Rosa / Moreno-Jiménez, Gemma / Domínguez-Acosta, Lourdes / Araiz-Ramírez, María / Hernández-Mateos, Luis / Flores-Ballesteros, Elena / Del Río-Garma, Julio / Pascual-Izquierdo, Cristina

    Blood

    2024  Volume 143, Issue 18, Page(s) 1807–1815

    Abstract: Abstract: Caplacizumab prevents the interaction between von Willebrand factor and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration ... ...

    Abstract Abstract: Caplacizumab prevents the interaction between von Willebrand factor and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes, 75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura. Caplacizumab shortened the time to platelet count normalization and reduced PEX requirement, exacerbations, and relapses. There was no difference in the time to achieve ADAMTS13 activity ≥20% after PEX end between caplacizumab-treated and nontreated episodes (median [interquartile range], 14.5 [7.7-27.2] vs 13.0 [8.0-29.0] days, P = .653). However, considering the 36 episodes in which caplacizumab was started ≤3 days after iTTP diagnosis, the time for ADAMTS13 restoration from PEX end was higher than in those episodes in which caplacizumab was started >3 days after iTTP diagnosis (20.0 [12.0-43.0] vs 11.0 [3.5-20.0] days, P = .003) or than in non-caplacizumab-treated episodes (P = .033). This finding could be related to a significantly shorter duration of PEX in early caplacizumab-treated episodes than in late caplacizumab-treated episodes (5.5 [4.0-9.0] vs 15.0 [11.0-21.5] days, P < .001) or non-caplacizumab-treated episodes (11.0 [6.0-26.0] days, P < .001). There were no differences in time to ADAMTS-13 restoration from PEX start (28.0 [17.2-47.5], 27.0 [19.0-37.5] and 29.5 [15.2-45.0] days in early caplacizumab-treated, late caplacizumab-treated and non-caplacizumab-treated episodes). Early administered caplacizumab does not prevent the requirement for immunosuppression but has beneficial effects by shortening PEX requirement without major safety concerns.
    MeSH term(s) Humans ; ADAMTS13 Protein/blood ; ADAMTS13 Protein/metabolism ; Purpura, Thrombotic Thrombocytopenic/drug therapy ; Purpura, Thrombotic Thrombocytopenic/therapy ; Male ; Female ; Single-Domain Antibodies/therapeutic use ; Adult ; Middle Aged ; Plasma Exchange ; Platelet Count ; Acute Disease ; Treatment Outcome ; Aged
    Chemical Substances ADAMTS13 Protein (EC 3.4.24.87) ; caplacizumab (2R27AB6766) ; ADAMTS13 protein, human (EC 3.4.24.87) ; Single-Domain Antibodies
    Language English
    Publishing date 2024-05-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023022725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: COVID-19 Vaccines and Autoimmune Hematologic Disorders

    María Eva Mingot-Castellano / Nora Butta / Mariana Canaro / María del Carmen Gómez del Castillo Solano / Blanca Sánchez-González / Reyes Jiménez-Bárcenas / Cristina Pascual-Izquierdo / Gonzalo Caballero-Navarro / Laura Entrena Ureña / Tomás José González-López / on behalf of the GEPTI

    Vaccines, Vol 10, Iss 961, p

    2022  Volume 961

    Abstract: Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally ... ...

    Abstract Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible.
    Keywords COVID-19 ; vaccines ; ITP ; VITT ; TTP ; AIHA and Evans syndrome ; Medicine ; R
    Subject code 005
    Language English
    Publishing date 2022-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Adherence to prophylaxis in adult patients with severe haemophilia A.

    Bonanad, Santiago / García-Dasí, María / Aznar, José A / Mingot-Castellano, María Eva / Jiménez-Yuste, Victor / Calle, MªVictoria / Palma, Antonio / López-Fernández, María Fernanda / Marco, Pascual / Paloma, María José / Fernández-Mosteirin, Nuria / Galmés, Bernat / Sanabria, Martín / Álvarez, MªPilar

    Haemophilia : the official journal of the World Federation of Hemophilia

    2020  Volume 26, Issue 5, Page(s) 800–808

    Abstract: Introduction: Adherence is a cornerstone of factor VIII prophylactic treatment. Information regarding the factors with potential influence on adherence is limited, particularly in adult patients.: Aim: To assess adherence in adult patients with ... ...

    Abstract Introduction: Adherence is a cornerstone of factor VIII prophylactic treatment. Information regarding the factors with potential influence on adherence is limited, particularly in adult patients.
    Aim: To assess adherence in adult patients with severe haemophilia A receiving prophylactic treatment in a real-life setting, and investigate the factors influencing adherence.
    Methods: Observational, prospective study including adult patients receiving factor VIII therapy in 15 Spanish centres. Patients recorded infusion doses on a logbook and answered various questionnaires to assess their health beliefs. Adherence rate was the percentage of infused doses over the prescribed ones. Self-perceived adherence was assessed using the VERITAS-Pro questionnaire, the psychometric properties of which were validated in the Spanish population. The relationship between adherence rate and treatment, clinical and demographic characteristics, health beliefs and perceived self-efficacy was investigated.
    Results: A total of 66 patients were followed up for 12 months. Mean adherence rate at the end of follow-up was 82.5%. Most of the study patients (n = 53, 80.3%) showed a moderate-to-high adherence rate (>70%). The VERITAS-Pro revealed a high perception of adherence. Multivariate analyses to predict treatment adherence identified the knee as a target joint and longer treatment duration as variables with significant (negative) influence on adherence. Adherence rate was not influenced by the patient's health beliefs or perceived self-efficacy.
    Conclusion: Most adult patients receiving factor VIII prophylactic treatment in Spain have moderate-to-high treatment adherence. Treatment duration and the knee as a target joint are factors with a moderate negative influence on treatment adherence.
    MeSH term(s) Adolescent ; Adult ; Female ; Hemophilia A/drug therapy ; Humans ; Male ; Medication Adherence ; Middle Aged ; Young Adult
    Language English
    Publishing date 2020-07-22
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1229713-6
    ISSN 1365-2516 ; 1351-8216 ; 1355-0691
    ISSN (online) 1365-2516
    ISSN 1351-8216 ; 1355-0691
    DOI 10.1111/hae.14039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4249: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 450: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).

    Mingot-Castellano, María Eva / Canaro Hirnyk, Mariana / Sánchez-González, Blanca / Álvarez-Román, María Teresa / Bárez-García, Abelardo / Bernardo-Gutiérrez, Ángel / Bernat-Pablo, Silvia / Bolaños-Calderón, Estefanía / Butta-Coll, Nora / Caballero-Navarro, Gonzalo / Caparrós-Miranda, Isabel Socorro / Entrena-Ureña, Laura / Fernández-Fuertes, Luis Fernando / García-Frade, Luis Javier / Gómez Del Castillo, María Del Carmen / González-López, Tomás José / Grande-García, Carlos / Guinea de Castro, José María / Jarque-Ramos, Isidro /
    Jiménez-Bárcenas, Reyes / López-Ansoar, Elsa / Martínez-Carballeira, Daniel / Martínez-Robles, Violeta / Monteagudo-Montesinos, Emilio / Páramo-Fernández, José Antonio / Perera-Álvarez, María Del Mar / Soto-Ortega, Inmaculada / Valcárcel-Ferreiras, David / Pascual-Izquierdo, Cristina

    Journal of clinical medicine

    2023  Volume 12, Issue 20

    Abstract: Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical ... ...

    Abstract Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical course hampers personalized approaches for diagnosis and management. In 2021, the Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH) updated a consensus document that had been launched in 2011. The updated guidelines have been the reference for the diagnosis and management of primary ITP in Spain ever since. Nevertheless, the emergence of new tools and strategies makes it advisable to review them again. For this reason, we have updated the main recommendations appropriately. Our aim is to provide a practical tool to facilitate the integral management of all aspects of primary ITP management.
    Language English
    Publishing date 2023-10-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12206422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top